Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of low-dose triamcinolone acetonide injections in reducing stricture at stapled hemorrhoidopexy sites.

Annals of coloproctology·2026
Same author

Coupling urea wastewater treatment with hydrogen production using interface-engineered copper oxide-graphitic carbon catalysts.

Environmental research·2026
Same author

Unveiling the critical role of strain-induced local structure changes in Co-N<sub>4</sub> single-atom catalysts for enhanced oxygen reduction and evolution reactions.

Nanoscale·2026
Same author

Herpes zoster vaccination and the risk reduction of ophthalmic diseases: A nationwide emulated target trial in South Korea.

Vaccine·2026
Same author

A case of systemic sclerosis with anti-SSSCA1 antibody: A possible link to prostate cancer.

JAAD case reports·2026
Same author

From prediction to action: a retrospective observational study on the real-world implementation of Critical Interventions (CrIs), an AI-based clinical decision support system changing clinical behavior in the emergency department.

BMC medical informatics and decision making·2025

Related Experiment Video

Updated: Jan 13, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy.

Hyuk Moon1, Hyunjung Park1, Soyun Lee1

  • 1Department of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, Gyeonggi-do, Republic of Korea.

Pharmaceutics
|October 29, 2025
PubMed
Summary
This summary is machine-generated.

The RAS/MAPK pathway drives cancer, and while BRAF/MEK inhibitors work, resistance is common. Kinase suppressor of Ras 1 (KSR1) is a key regulator, and targeting it shows promise for cancer therapy, especially hepatocellular carcinoma.

Keywords:
RAS/MAPK signalinghepatocellular carcinomakinase suppressor of Ras 1scaffold proteintargeted therapy

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.7K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

Related Experiment Videos

Last Updated: Jan 13, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.7K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Carcinogenesis involves dysregulated signaling pathways like RAS/RAF/MEK/ERK (RAS/MAPK).
  • BRAF and MEK inhibitors show success but face adaptive resistance, necessitating exploration of other pathway targets.
  • Kinase suppressor of Ras 1 (KSR1), a scaffold protein, is increasingly recognized as an active regulator of RAS/MAPK signaling.

Purpose of the Study:

  • To provide a comprehensive review of accessory and scaffold proteins in the RAS/MAPK pathway.
  • To focus on the structural and functional properties of KSR1.
  • To summarize preclinical evidence and discuss the therapeutic potential of KSR1-targeted interventions in cancer, particularly hepatocellular carcinoma (HCC).

Main Methods:

  • Literature review focusing on RAS/MAPK pathway components and KSR1.
  • Analysis of preclinical data on KSR1 function and inhibition.
  • Synthesis of information on KSR1's role in cancer proliferation and survival.

Main Results:

  • KSR1 overexpression promotes cancer cell proliferation and survival.
  • Inhibition of KSR1 attenuates RAS/MAPK signaling and suppresses tumor growth in preclinical models.
  • KSR1 is a promising therapeutic target for various cancers.

Conclusions:

  • KSR1 is a critical regulator of RAS/MAPK signaling and a potential therapeutic target.
  • Targeting KSR1 offers a strategy to overcome resistance to existing therapies.
  • Further investigation into KSR1-based therapies, especially for HCC, is warranted.